Merck's Keytruda Is First Checkpoint Inhibitor To Win US Approval Based On TMB Biomarker

 
• By Jessica Merrill

Merck has secured FDA approval for Keytruda for use in tumors with high tumor mutational burden, something Bristol's Opdivo and AstraZeneca's Imfinzi were not able to do in lung cancer.

Athlete in action of high jump.
Keytruda clears a bar for use in TMB-high tumors • Source: Shutterstock

More from New Products

More from Scrip